首页 > 最新文献

Canadian Journal of Kidney Health and Disease最新文献

英文 中文
Point-of-Care Ultrasonography and Worsening of Renal Function in Acute Heart Failure: A Cohort Study. 急诊超声检查与急性心力衰竭肾功能恶化:一项队列研究。
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-07-29 eCollection Date: 2025-01-01 DOI: 10.1177/20543581251328069
Guillaume Soret, Antonio Leidi, Alexandre Leszek, Christophe Marti, Sebastian Carballo, Jérôme Stirnemann, Olivier Grosgurin, Jean-Luc Reny, Thomas A Mavrakanas

Introduction: The goal of this study was to investigate the association between worsening renal function (WRF) and central venous pressure, right ventricular function, and lung fluid overload assessed by point-of-care ultrasound (POCUS) in hospitalized patients with acute heart failure (AHF).

Methods: This was a prospective cohort study including AHF adult inpatients, conducted in Geneva University Hospitals from October 2019 to March 2020. The primary outcome was WRF, defined by an increase in creatinine of ≥1.5 times from baseline value or an increase of ≥0.3 mg/dL between admission and day 4 to 6. Expert ultrasonographers used POCUS to examine lungs, inferior vena cava during spontaneous expiration (IVCe), and tricuspid annular plane systolic excursion (TAPSE) at admission.

Results: A total of 43 patients were included in the study. A total of 8 patients (19%) developed WRF during the study period (between October 8, 2019 and March 16, 2020), of whom 4 were in the higher quartile of lung fluid overload, 2 had TAPSE <14 mm, and 4 had IVCe ≥ 21 mm. In uni- and multi-variate logistic regression model, neither admission IVCe nor TAPSE was associated with WRF. However, lung congestion, as assessed by the number of B-lines, was significantly associated with WRF (odds ratio [OR] per quartile = 2.47, 95% confidence interval [CI] = 1.01 to 5.86, P = .04). This result remained statistically significant after adjustment for daily diuretic dose in mg/kg (OR = 2.98, 95% CI = 1.11 to 8.00, P = .03).

Conclusion: This study showed that lung congestion as assessed by POCUS was associated with WRF in AHF patients, whereas IVCe and TAPSE were not. Due to the small number of participants, our results need to be prospectively validated in future adequately powered clinical trials.

本研究的目的是探讨急性心力衰竭(AHF)住院患者的肾功能(WRF)恶化与中心静脉压、右心室功能和肺液过载之间的关系,该关系由即时超声(POCUS)评估。方法:这是一项前瞻性队列研究,包括2019年10月至2020年3月在日内瓦大学医院进行的AHF成年住院患者。主要终点为WRF,定义为入院至第4 - 6天肌酐较基线值增加≥1.5倍或增加≥0.3 mg/dL。专家超声医师在入院时使用POCUS检查肺部、自发性呼气时的下腔静脉(IVCe)和三尖瓣环状收缩平面漂移(TAPSE)。结果:共纳入43例患者。在研究期间(2019年10月8日至2020年3月16日),共有8例(19%)患者发生WRF,其中4例处于肺液过载高四分位数,2例TAPSE P = 0.04)。调整利尿剂日剂量(mg/kg)后,该结果仍具有统计学意义(OR = 2.98, 95% CI = 1.11 ~ 8.00, P = 0.03)。结论:本研究表明,POCUS评估的肺充血与AHF患者的WRF有关,而IVCe和TAPSE与WRF无关。由于参与者数量少,我们的结果需要在未来充分有力的临床试验中进行前瞻性验证。
{"title":"Point-of-Care Ultrasonography and Worsening of Renal Function in Acute Heart Failure: A Cohort Study.","authors":"Guillaume Soret, Antonio Leidi, Alexandre Leszek, Christophe Marti, Sebastian Carballo, Jérôme Stirnemann, Olivier Grosgurin, Jean-Luc Reny, Thomas A Mavrakanas","doi":"10.1177/20543581251328069","DOIUrl":"10.1177/20543581251328069","url":null,"abstract":"<p><strong>Introduction: </strong>The goal of this study was to investigate the association between worsening renal function (WRF) and central venous pressure, right ventricular function, and lung fluid overload assessed by point-of-care ultrasound (POCUS) in hospitalized patients with acute heart failure (AHF).</p><p><strong>Methods: </strong>This was a prospective cohort study including AHF adult inpatients, conducted in Geneva University Hospitals from October 2019 to March 2020. The primary outcome was WRF, defined by an increase in creatinine of ≥1.5 times from baseline value or an increase of ≥0.3 mg/dL between admission and day 4 to 6. Expert ultrasonographers used POCUS to examine lungs, inferior vena cava during spontaneous expiration (IVCe), and tricuspid annular plane systolic excursion (TAPSE) at admission.</p><p><strong>Results: </strong>A total of 43 patients were included in the study. A total of 8 patients (19%) developed WRF during the study period (between October 8, 2019 and March 16, 2020), of whom 4 were in the higher quartile of lung fluid overload, 2 had TAPSE <14 mm, and 4 had IVCe ≥ 21 mm. In uni- and multi-variate logistic regression model, neither admission IVCe nor TAPSE was associated with WRF. However, lung congestion, as assessed by the number of B-lines, was significantly associated with WRF (odds ratio [OR] per quartile = 2.47, 95% confidence interval [CI] = 1.01 to 5.86, <i>P</i> = .04). This result remained statistically significant after adjustment for daily diuretic dose in mg/kg (OR = 2.98, 95% CI = 1.11 to 8.00, <i>P</i> = .03).</p><p><strong>Conclusion: </strong>This study showed that lung congestion as assessed by POCUS was associated with WRF in AHF patients, whereas IVCe and TAPSE were not. Due to the small number of participants, our results need to be prospectively validated in future adequately powered clinical trials.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251328069"},"PeriodicalIF":1.5,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers to, and Facilitators of, Diabetes Self-management in the Dialysis Population: A Narrative Review and Implications for Research. 透析人群糖尿病自我管理的障碍和促进因素:一个叙述性的回顾和研究意义。
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-07-29 eCollection Date: 2025-01-01 DOI: 10.1177/20543581251359734
Kokab Younis, Graham McCaffrey, Kathryn King Shier, Shelley Raffin Bouchal, Robert R Quinn

Purpose of review: Patients with both diabetes and kidney failure requiring dialysis are a complex population that is at risk of diabetes-related complications, hospitalizations, and mortality. Due to the significant illness burden, self-management of diabetes becomes challenging. The purpose of this review was to identify and synthesize the literature on barriers to, and facilitators of, diabetes self-management among patients with both diabetes and kidney failure requiring dialysis.

Sources of information: We conducted a search of health care databases (CINAHL, PubMed, OVID Medline) to find studies that were focused on exploring barriers to, and facilitators of, diabetes self-management in this population. We included English-language qualitative, quantitative, and mixed-methods studies.

Methods: We performed a focused narrative review assessing barriers and facilitators to diabetes management among patients with chronic kidney disease. The literature was critically analyzed using various appraisal tools, and thematic analysis was performed.

Key findings: A total of 134 articles were identified. Eight articles met inclusion criteria. A review of the articles revealed barriers in diabetes self-management covering 5 themes: financial limitations, limited access to healthcare services, siloed and fragmented care, increased complexity of the dietary regimen, and the higher burden of health. Three themes were revealed pertaining to facilitators of diabetes self-management: self-management support and education, coordinated care between healthcare providers, and family support.

Limitations: The literature search was in-depth and comprehensive, but not exhaustive. Also, we restricted our search criteria to articles published in the English language.

Implications: There can be challenges living with multiple chronic conditions, especially for those with comorbid diabetes and kidney failure requiring dialysis. This study underscores the urgent need for quality improvement and research initiatives to support these individuals. In addition, conducting further qualitative research to explore the perspectives of dialysis patients, their health care professionals, and caregivers would be beneficial.

综述目的:需要透析的糖尿病和肾衰竭患者是一个复杂的人群,存在糖尿病相关并发症、住院和死亡的风险。由于严重的疾病负担,糖尿病的自我管理变得具有挑战性。本综述的目的是识别和综合有关需要透析的糖尿病和肾衰竭患者糖尿病自我管理障碍和促进因素的文献。信息来源:我们对医疗数据库(CINAHL, PubMed, OVID Medline)进行了搜索,以找到专注于探索该人群糖尿病自我管理障碍和促进因素的研究。我们纳入了英语定性、定量和混合方法研究。方法:我们进行了一项集中的叙述性综述,评估慢性肾脏疾病患者糖尿病管理的障碍和促进因素。使用各种评估工具对文献进行批判性分析,并进行专题分析。主要发现:共发现134篇文章。8篇文章符合纳入标准。对这些文章的回顾揭示了糖尿病自我管理的障碍,涉及5个主题:财政限制、获得医疗保健服务的机会有限、孤立和分散的护理、饮食方案的复杂性增加以及更高的健康负担。三个主题揭示了有关促进糖尿病自我管理:自我管理支持和教育,卫生保健提供者之间的协调护理和家庭支持。局限性:文献检索是深入和全面的,但不是详尽的。此外,我们将搜索标准限制在以英语发表的文章上。意义:患有多种慢性疾病的患者可能面临挑战,特别是那些合并糖尿病和肾衰竭需要透析的患者。这项研究强调了质量改进和研究倡议的迫切需要,以支持这些个人。此外,进行进一步的定性研究,以探索透析患者,他们的卫生保健专业人员和护理人员的观点将是有益的。
{"title":"Barriers to, and Facilitators of, Diabetes Self-management in the Dialysis Population: A Narrative Review and Implications for Research.","authors":"Kokab Younis, Graham McCaffrey, Kathryn King Shier, Shelley Raffin Bouchal, Robert R Quinn","doi":"10.1177/20543581251359734","DOIUrl":"10.1177/20543581251359734","url":null,"abstract":"<p><strong>Purpose of review: </strong>Patients with both diabetes and kidney failure requiring dialysis are a complex population that is at risk of diabetes-related complications, hospitalizations, and mortality. Due to the significant illness burden, self-management of diabetes becomes challenging. The purpose of this review was to identify and synthesize the literature on barriers to, and facilitators of, diabetes self-management among patients with both diabetes and kidney failure requiring dialysis.</p><p><strong>Sources of information: </strong>We conducted a search of health care databases (CINAHL, PubMed, OVID Medline) to find studies that were focused on exploring barriers to, and facilitators of, diabetes self-management in this population. We included English-language qualitative, quantitative, and mixed-methods studies.</p><p><strong>Methods: </strong>We performed a focused narrative review assessing barriers and facilitators to diabetes management among patients with chronic kidney disease. The literature was critically analyzed using various appraisal tools, and thematic analysis was performed.</p><p><strong>Key findings: </strong>A total of 134 articles were identified. Eight articles met inclusion criteria. A review of the articles revealed barriers in diabetes self-management covering 5 themes: financial limitations, limited access to healthcare services, siloed and fragmented care, increased complexity of the dietary regimen, and the higher burden of health. Three themes were revealed pertaining to facilitators of diabetes self-management: self-management support and education, coordinated care between healthcare providers, and family support.</p><p><strong>Limitations: </strong>The literature search was in-depth and comprehensive, but not exhaustive. Also, we restricted our search criteria to articles published in the English language.</p><p><strong>Implications: </strong>There can be challenges living with multiple chronic conditions, especially for those with comorbid diabetes and kidney failure requiring dialysis. This study underscores the urgent need for quality improvement and research initiatives to support these individuals. In addition, conducting further qualitative research to explore the perspectives of dialysis patients, their health care professionals, and caregivers would be beneficial.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251359734"},"PeriodicalIF":1.5,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impacts of the COVID-19 Pandemic on Chronic Kidney Disease Care: Perspectives of Health Care Providers. COVID-19大流行对慢性肾脏疾病护理的影响:卫生保健提供者的观点
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-07-27 eCollection Date: 2025-01-01 DOI: 10.1177/20543581251355024
Erin Hedin, David B Nicholas, Andrew Mantulak, Marcello Tonelli, Rosslynn T Zulla, R Todd Alexander

Background: The COVID-19 pandemic significantly disrupted health care delivery; however, limited research attention has addressed the impacts of the pandemic specifically on renal-based health care.

Objective: The aim of the study was to understand the health and psychosocial impacts of the COVID-19 pandemic on care delivery as well as on health care providers (HCPs).

Design: A qualitative Interpretive Description approach was used.

Setting: Participants were recruited from kidney care units in Alberta and Ontario, Canada.

Participants: 46 interdisciplinary HCPs providing kidney care during the pandemic participated in the study. Participants comprised pediatric (n=9) and adult (n=37) HCPs.

Methods: Qualitative focus groups were facilitated. They were conducted using Zoom (Version 6.3.11).

Results: Research results indicated substantial strain on patients and HCPs during the COVID-19 pandemic, including mental health difficulties. For HCPs, moral distress was experienced from witnessing negative impacts of the pandemic and care shifts on patients. HCPs were further deleteriously affected by staffing shortages, facility limitations due to care interruptions and resource gaps in health and community systems. Conversely, participants identified concurrent benefits from pandemic-related shifts such as the rapid transition to virtual care. While virtual care imposed challenges for physical assessment of patients, patient convenience and increased access to HCPs were noted. With training, support and experience, HCPs and patients reported an appreciation for communication offered by virtual care where appropriate. Supportive unit leaders and peer support from HCP colleagues were viewed to make this difficult experience of the pandemic more manageable. HCPs drew strength in being able to support their patients despite the difficulties of the pandemic.

Limitations: Firsthand experiences of patients and families were not offered in this article, although their perspectives were elicited in another arm of this study. A more specific focus on pediatric versus adult systems of care, and the impacts of the pandemic on various disciplines, would add depth to understanding the unique impacts of the pandemic on various areas of care and across disciplines.

Conclusions: Study results call for the advancement of clinical care and heightened consideration of HCP needs in a pandemic. Included recommendations are ensuring sufficient resources, prudent use of communication technology, and optimizing support to HCPs.

背景:COVID-19大流行严重扰乱了卫生保健服务;然而,有限的研究关注已经解决了大流行的影响,特别是对肾脏卫生保健。目的:本研究的目的是了解COVID-19大流行对医疗服务和卫生保健提供者(HCPs)的健康和心理社会影响。设计:采用定性解释性描述方法。环境:参与者从加拿大阿尔伯塔省和安大略省的肾脏护理单位招募。参与者:46名在大流行期间提供肾脏护理的跨学科医护人员参与了这项研究。参与者包括儿科(n=9)和成人(n=37) HCPs。方法:采用定性焦点小组法。使用Zoom (Version 6.3.11)进行测试。结果:研究结果表明,在COVID-19大流行期间,患者和医务人员承受了巨大压力,包括精神健康困难。对于医务人员来说,目睹了大流行的负面影响和对患者的护理转变,经历了道德上的痛苦。医护人员短缺、由于护理中断而造成的设施限制以及卫生和社区系统的资源缺口,进一步对卫生服务提供者造成了有害影响。相反,与会者确定了与大流行相关的转变(如迅速过渡到虚拟护理)的同时益处。虽然虚拟护理给患者的身体评估带来了挑战,但注意到患者的便利性和获得hcp的机会增加。有了培训、支持和经验,医护人员和患者报告说,他们对虚拟护理在适当情况下提供的交流表示赞赏。人们认为,单位领导的支持和卫生控制中心同事的同伴支持使大流行的这一艰难经历更易于管理。尽管面临大流行的困难,医务人员仍有能力为病人提供支持。局限性:本文没有提供患者和家属的第一手经验,尽管他们的观点在本研究的另一个方面得到了启发。更具体地关注儿科与成人护理系统,以及大流行对各个学科的影响,将有助于深入了解大流行对各个护理领域和跨学科的独特影响。结论:研究结果呼吁提高临床护理水平,并在大流行期间加强对HCP需求的考虑。所包括的建议包括确保充足的资源、谨慎使用通信技术以及优化对卫生保健专业人员的支持。
{"title":"Impacts of the COVID-19 Pandemic on Chronic Kidney Disease Care: Perspectives of Health Care Providers.","authors":"Erin Hedin, David B Nicholas, Andrew Mantulak, Marcello Tonelli, Rosslynn T Zulla, R Todd Alexander","doi":"10.1177/20543581251355024","DOIUrl":"10.1177/20543581251355024","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic significantly disrupted health care delivery; however, limited research attention has addressed the impacts of the pandemic specifically on renal-based health care.</p><p><strong>Objective: </strong>The aim of the study was to understand the health and psychosocial impacts of the COVID-19 pandemic on care delivery as well as on health care providers (HCPs).</p><p><strong>Design: </strong>A qualitative Interpretive Description approach was used.</p><p><strong>Setting: </strong>Participants were recruited from kidney care units in Alberta and Ontario, Canada.</p><p><strong>Participants: </strong>46 interdisciplinary HCPs providing kidney care during the pandemic participated in the study. Participants comprised pediatric (n=9) and adult (n=37) HCPs.</p><p><strong>Methods: </strong>Qualitative focus groups were facilitated. They were conducted using Zoom (Version 6.3.11).</p><p><strong>Results: </strong>Research results indicated substantial strain on patients and HCPs during the COVID-19 pandemic, including mental health difficulties. For HCPs, moral distress was experienced from witnessing negative impacts of the pandemic and care shifts on patients. HCPs were further deleteriously affected by staffing shortages, facility limitations due to care interruptions and resource gaps in health and community systems. Conversely, participants identified concurrent benefits from pandemic-related shifts such as the rapid transition to virtual care. While virtual care imposed challenges for physical assessment of patients, patient convenience and increased access to HCPs were noted. With training, support and experience, HCPs and patients reported an appreciation for communication offered by virtual care where appropriate. Supportive unit leaders and peer support from HCP colleagues were viewed to make this difficult experience of the pandemic more manageable. HCPs drew strength in being able to support their patients despite the difficulties of the pandemic.</p><p><strong>Limitations: </strong>Firsthand experiences of patients and families were not offered in this article, although their perspectives were elicited in another arm of this study. A more specific focus on pediatric versus adult systems of care, and the impacts of the pandemic on various disciplines, would add depth to understanding the unique impacts of the pandemic on various areas of care and across disciplines.</p><p><strong>Conclusions: </strong>Study results call for the advancement of clinical care and heightened consideration of HCP needs in a pandemic. Included recommendations are ensuring sufficient resources, prudent use of communication technology, and optimizing support to HCPs.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251355024"},"PeriodicalIF":1.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "Is childhood IgA nephropathy different from adult IgA nephropathy? A narrative review". 儿童IgA肾病与成人IgA肾病不同吗?叙述性评论”。
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-07-22 eCollection Date: 2025-01-01 DOI: 10.1177/20543581251359782

[This corrects the article DOI: 10.1177/20543581251322571.].

[这更正了文章DOI: 10.1177/20543581251322571.]。
{"title":"Corrigendum to \"Is childhood IgA nephropathy different from adult IgA nephropathy? A narrative review\".","authors":"","doi":"10.1177/20543581251359782","DOIUrl":"10.1177/20543581251359782","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/20543581251322571.].</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251359782"},"PeriodicalIF":1.5,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Outcomes and Health Care Utilization in Patients with Advanced Chronic Kidney Disease not on Dialysis After the Onset of the COVID-19 Pandemic in Ontario, Canada. 加拿大安大略省2019冠状病毒病大流行后未透析的晚期慢性肾病患者的临床结局和医疗保健利用
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-07-03 eCollection Date: 2025-01-01 DOI: 10.1177/20543581251350030
Carol Wang, Yuguang Kang, Stephanie N Dixon, Nivethika Jeyakumar, K Scott Brimble, Amit X Garg, Peter G Blake, Therese A Stukel, Matthew J Oliver, Ahmed Al-Jaishi, Kristin K Clemens, Longdi Fu, Jane Ip, Susan McKenzie, Louise Moist, Amber O Molnar, Flory Muanda-Tsobo, Marian Reich, Pavel Roshanov, Samuel A Silver, Ronald Wald, Matthew A Weir, Kevin Yau, Ann Young, Kyla L Naylor
<p><strong>Background: </strong>The COVID-19 pandemic caused considerable disruption to health care services. Limited data exist on its impacts on clinical outcomes and health care utilization in patients with advanced chronic kidney disease (CKD).</p><p><strong>Objective: </strong>To compare the rates of all-cause mortality, cardiovascular-related hospitalizations, kidney-related outcomes, and health care utilization in patients with advanced CKD before and during the first 21 months of the COVID-19 pandemic.</p><p><strong>Design: </strong>Population-based, repeated cross-sectional study from March 15, 2017 to November 15, 2021, with follow-up until December 14, 2021 (preceding the Omicron variant).</p><p><strong>Setting: </strong>Linked administrative health care databases from Ontario, Canada.</p><p><strong>Participants: </strong>Adult patients with advanced CKD, defined as an estimated glomerular filtration rate <30 mL/min/1.73 m<sup>2</sup> (excluding patients receiving maintenance dialysis).</p><p><strong>Measurements: </strong>The pre-COVID-19 period was from March 15, 2017 to March 14, 2020 and the COVID-19 period was from March 15, 2020 to December 14, 2021. Poisson generalized estimating equations were used to predict post-COVID-19 patient outcomes and health utilization based on pre-COVID trends, estimating relative changes between the observed and expected outcomes. The multivariable model incorporated age group-sex interaction terms, a continuous variable denoting time in months to capture general trends, and pre-COVID month indicators to adjust for seasonal changes.</p><p><strong>Methods: </strong>Our primary outcome was all-cause mortality. Secondary outcomes included all-cause hospitalizations, non-COVID-19-related deaths and hospitalizations, intensive care unit (ICU) admissions, mechanical ventilation, and emergency room visits. We also examined cardiovascular-related hospitalizations, kidney-related outcomes, and ambulatory visits.</p><p><strong>Results: </strong>We included 101 688 adults with advanced CKD. The incidence of all-cause mortality was 147.4 (95% confidence interval [CI] = 145.1, 149.7) per 1000 person-years in the pre-COVID-19 period compared to 150.8 (95% CI = 147.9, 153.7) per 1000 person-years in the COVID-19 period. After adjustment, there was an 8% higher rate of all-cause mortality during the COVID-19 (adjusted relative rate [aRR] = 1.08, 95% CI = 1.03, 1.12). Non-COVID-19-related deaths did not increase substantially (aRR = 1.02, 95% CI = 0.97, 1.07). The COVID-19 period was associated with a lower rate of all-cause hospitalizations, ICU admissions, and emergency room visits. There were declines in long-term care admissions and non-nephrology physician visits in the first 3 months of the pandemic. In contrast, nephrology visits remained stable throughout the study period, including the first 3 months of the pandemic. Similarly, the monthly rates of acute kidney injury requiring dialysis initiation showed li
背景:COVID-19大流行对卫生保健服务造成了相当大的干扰。关于其对晚期慢性肾脏疾病(CKD)患者临床结果和医疗保健利用的影响的数据有限。目的:比较COVID-19大流行前和前21个月期间晚期CKD患者的全因死亡率、心血管相关住院率、肾脏相关结局和医疗保健利用率。设计:2017年3月15日至2021年11月15日,以人群为基础的重复横断面研究,随访至2021年12月14日(在Omicron变异之前)。设置:链接来自加拿大安大略省的行政卫生保健数据库。参与者:成年晚期CKD患者,定义为肾小球滤过率2(不包括接受维持性透析的患者)。测量方法:2019冠状病毒病前期为2017年3月15日至2020年3月14日,COVID-19期为2020年3月15日至2021年12月14日。使用泊松广义估计方程预测covid -19后患者的结果和基于covid -19前趋势的健康利用,估计观察结果和预期结果之间的相对变化。多变量模型纳入了年龄组-性别相互作用项,这是一个连续变量,表示以月为单位的时间,以捕捉总体趋势,以及covid前月份指标,以调整季节性变化。方法:我们的主要终点是全因死亡率。次要结局包括全因住院、与covid -19无关的死亡和住院、重症监护病房(ICU)入院、机械通气和急诊室就诊。我们还检查了心血管相关住院、肾脏相关结局和门诊就诊。结果:我们纳入了101 688名成人晚期CKD患者。COVID-19前期的全因死亡率为147.4(95%可信区间[CI] = 145.1, 149.7) / 1000人年,而COVID-19期间的全因死亡率为150.8 (95% CI = 147.9, 153.7) / 1000人年。调整后,新冠肺炎期间的全因死亡率高出8%(调整后的相对死亡率[aRR] = 1.08, 95% CI = 1.03, 1.12)。与covid -19无关的死亡人数没有显著增加(aRR = 1.02, 95% CI = 0.97, 1.07)。COVID-19期间,全因住院率、ICU入院率和急诊室就诊率均较低。在大流行的前3个月,长期护理住院人数和非肾脏病医生就诊人数有所下降。相比之下,在整个研究期间,包括大流行的前3个月,肾脏病就诊保持稳定。同样,每月需要开始透析的急性肾损伤发生率与大流行前的水平相比变化不大。局限性:由于分析时的数据可用性,我们没有研究2021年12月以后COVID-19大流行对晚期CKD患者的影响。结论:在大流行的前21个月期间,尽管医疗保健使用率有所下降,但与covid -19无关的死亡人数并未增加。这项研究为今后卫生保健紧急情况的卫生服务规划提供了信息。
{"title":"Clinical Outcomes and Health Care Utilization in Patients with Advanced Chronic Kidney Disease not on Dialysis After the Onset of the COVID-19 Pandemic in Ontario, Canada.","authors":"Carol Wang, Yuguang Kang, Stephanie N Dixon, Nivethika Jeyakumar, K Scott Brimble, Amit X Garg, Peter G Blake, Therese A Stukel, Matthew J Oliver, Ahmed Al-Jaishi, Kristin K Clemens, Longdi Fu, Jane Ip, Susan McKenzie, Louise Moist, Amber O Molnar, Flory Muanda-Tsobo, Marian Reich, Pavel Roshanov, Samuel A Silver, Ronald Wald, Matthew A Weir, Kevin Yau, Ann Young, Kyla L Naylor","doi":"10.1177/20543581251350030","DOIUrl":"10.1177/20543581251350030","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The COVID-19 pandemic caused considerable disruption to health care services. Limited data exist on its impacts on clinical outcomes and health care utilization in patients with advanced chronic kidney disease (CKD).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To compare the rates of all-cause mortality, cardiovascular-related hospitalizations, kidney-related outcomes, and health care utilization in patients with advanced CKD before and during the first 21 months of the COVID-19 pandemic.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Population-based, repeated cross-sectional study from March 15, 2017 to November 15, 2021, with follow-up until December 14, 2021 (preceding the Omicron variant).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;Linked administrative health care databases from Ontario, Canada.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;Adult patients with advanced CKD, defined as an estimated glomerular filtration rate &lt;30 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; (excluding patients receiving maintenance dialysis).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Measurements: &lt;/strong&gt;The pre-COVID-19 period was from March 15, 2017 to March 14, 2020 and the COVID-19 period was from March 15, 2020 to December 14, 2021. Poisson generalized estimating equations were used to predict post-COVID-19 patient outcomes and health utilization based on pre-COVID trends, estimating relative changes between the observed and expected outcomes. The multivariable model incorporated age group-sex interaction terms, a continuous variable denoting time in months to capture general trends, and pre-COVID month indicators to adjust for seasonal changes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Our primary outcome was all-cause mortality. Secondary outcomes included all-cause hospitalizations, non-COVID-19-related deaths and hospitalizations, intensive care unit (ICU) admissions, mechanical ventilation, and emergency room visits. We also examined cardiovascular-related hospitalizations, kidney-related outcomes, and ambulatory visits.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;We included 101 688 adults with advanced CKD. The incidence of all-cause mortality was 147.4 (95% confidence interval [CI] = 145.1, 149.7) per 1000 person-years in the pre-COVID-19 period compared to 150.8 (95% CI = 147.9, 153.7) per 1000 person-years in the COVID-19 period. After adjustment, there was an 8% higher rate of all-cause mortality during the COVID-19 (adjusted relative rate [aRR] = 1.08, 95% CI = 1.03, 1.12). Non-COVID-19-related deaths did not increase substantially (aRR = 1.02, 95% CI = 0.97, 1.07). The COVID-19 period was associated with a lower rate of all-cause hospitalizations, ICU admissions, and emergency room visits. There were declines in long-term care admissions and non-nephrology physician visits in the first 3 months of the pandemic. In contrast, nephrology visits remained stable throughout the study period, including the first 3 months of the pandemic. Similarly, the monthly rates of acute kidney injury requiring dialysis initiation showed li","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251350030"},"PeriodicalIF":1.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enablers and Barriers to Integrating Advance Care Planning in Chronic Kidney Disease Care in a Canadian Provincial Network. 在加拿大省级网络中整合慢性肾脏疾病护理的预先护理计划的推动因素和障碍。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-07-01 eCollection Date: 2025-01-01 DOI: 10.1177/20543581251350891
Helen H L Chiu, John Duncan, Sherri Lynn Kensall, Yanchini Rajmohan, Sushila Saunders, Sarah Thomas, Salma Wadhwania, Gaylene Hargrove

Background: Individuals with advanced chronic kidney disease benefit from an integrated palliative approach to care through timely advance care planning and discussions about their goals of care. Despite literature and guidelines emphasizing the need for advance care planning in chronic kidney disease management, treatment-focused approach remains the norm, partly due to provider reluctance and discomfort in engaging in advance care planning conversations. In British Columbia (BC), the Integrated Palliative Nephrology (IPN) project was launched to enhance kidney health care provider engagement in advance care planning and goals of care discussions, to train kidney health care providers in the province to initiate serious illness conversations, and to develop standardized resources for patients and providers across a provincial renal network.

Objective: As part of the quality improvement, this study highlights the barriers/challenges and enablers to engage in advance care planning for health care providers of adult patients with chronic kidney disease.

Design: A multi-methods approach was used.

Setting: British Columbia, Canada.

Participants: Kidney health care providers who worked in nondialysis and dialysis care settings.

Methods: Data were collected through semistructured surveys, individual interviews, and focus groups with health care providers across the province who care for patients with chronic kidney disease.

Results: The results of a kidney health care provider survey (n = 90) showed self-reported improvements in knowledge of the integrated palliative approach and competency and comfort engaging in advance care planning discussions. The results of one-on-one interviews (n = 15) and focus groups (n = 32) with kidney health care providers showed that taking a relational approach with patients, enhancing provider comfort and competency with advance care planning, clarifying roles and responsibilities around who should engage in advance care planning conversation was beneficial to patient care. Supporting cohesion among care teams around the goal of advancing an integrated palliative approach, and offering mentorship and targeted education and resources for the kidney care team, can enable effective advance care planning discussions.

Limitations: The study was limited by purposive sampling, a small sample size, and potential bias due to participant interests and settings.

Conclusions: For kidney health care providers, targeted education and resources, clarity around roles and responsibilities, and long-term relationships with patients may help advance the cultural shift from treatment focus to integrating palliative care across the continuum of the illness journey.

Trial registration: Not registered.

背景:患有晚期慢性肾脏疾病的个体可以通过及时的提前护理计划和讨论他们的护理目标,从综合姑息治疗方法中获益。尽管文献和指南强调在慢性肾脏疾病管理中需要预先护理计划,但以治疗为中心的方法仍然是常态,部分原因是提供者不愿意参与预先护理计划对话。在不列颠哥伦比亚省(BC),启动了综合姑息肾病学(IPN)项目,以加强肾脏保健提供者对预先护理计划和护理目标讨论的参与,培训该省肾脏保健提供者发起严重疾病对话,并为全省肾脏网络的患者和提供者开发标准化资源。目的:作为质量改进的一部分,本研究强调了成人慢性肾病患者的卫生保健提供者参与预先护理计划的障碍/挑战和推动因素。设计:采用多方法研究。环境:加拿大不列颠哥伦比亚省。参与者:在非透析和透析护理机构工作的肾脏保健提供者。方法:通过半结构化调查、个人访谈和对全省慢性肾脏疾病患者的卫生保健提供者的焦点小组收集数据。结果:一项肾脏保健提供者调查(n = 90)的结果显示,自我报告的综合姑息治疗方法的知识以及参与预先护理计划讨论的能力和舒适度有所改善。一对一访谈(n = 15)和焦点小组访谈(n = 32)的结果表明,与患者采取关系方法,提高提供者对预先护理计划的舒适度和能力,明确谁应该参与预先护理计划对话的角色和责任,有利于患者护理。围绕推进综合姑息治疗方法的目标,支持护理团队之间的凝聚力,并为肾脏护理团队提供指导和有针对性的教育和资源,可以实现有效的预先护理计划讨论。局限性:本研究受限于有目的的抽样,样本量小,以及由于参与者兴趣和环境造成的潜在偏倚。结论:对于肾脏卫生保健提供者来说,有针对性的教育和资源,明确角色和责任,以及与患者的长期关系可能有助于推动文化转变,从以治疗为重点到在整个疾病过程中整合姑息治疗。试验注册:未注册。
{"title":"Enablers and Barriers to Integrating Advance Care Planning in Chronic Kidney Disease Care in a Canadian Provincial Network.","authors":"Helen H L Chiu, John Duncan, Sherri Lynn Kensall, Yanchini Rajmohan, Sushila Saunders, Sarah Thomas, Salma Wadhwania, Gaylene Hargrove","doi":"10.1177/20543581251350891","DOIUrl":"10.1177/20543581251350891","url":null,"abstract":"<p><strong>Background: </strong>Individuals with advanced chronic kidney disease benefit from an integrated palliative approach to care through timely advance care planning and discussions about their goals of care. Despite literature and guidelines emphasizing the need for advance care planning in chronic kidney disease management, treatment-focused approach remains the norm, partly due to provider reluctance and discomfort in engaging in advance care planning conversations. In British Columbia (BC), the Integrated Palliative Nephrology (IPN) project was launched to enhance kidney health care provider engagement in advance care planning and goals of care discussions, to train kidney health care providers in the province to initiate serious illness conversations, and to develop standardized resources for patients and providers across a provincial renal network.</p><p><strong>Objective: </strong>As part of the quality improvement, this study highlights the barriers/challenges and enablers to engage in advance care planning for health care providers of adult patients with chronic kidney disease.</p><p><strong>Design: </strong>A multi-methods approach was used.</p><p><strong>Setting: </strong>British Columbia, Canada.</p><p><strong>Participants: </strong>Kidney health care providers who worked in nondialysis and dialysis care settings.</p><p><strong>Methods: </strong>Data were collected through semistructured surveys, individual interviews, and focus groups with health care providers across the province who care for patients with chronic kidney disease.</p><p><strong>Results: </strong>The results of a kidney health care provider survey (n = 90) showed self-reported improvements in knowledge of the integrated palliative approach and competency and comfort engaging in advance care planning discussions. The results of one-on-one interviews (n = 15) and focus groups (n = 32) with kidney health care providers showed that taking a relational approach with patients, enhancing provider comfort and competency with advance care planning, clarifying roles and responsibilities around who should engage in advance care planning conversation was beneficial to patient care. Supporting cohesion among care teams around the goal of advancing an integrated palliative approach, and offering mentorship and targeted education and resources for the kidney care team, can enable effective advance care planning discussions.</p><p><strong>Limitations: </strong>The study was limited by purposive sampling, a small sample size, and potential bias due to participant interests and settings.</p><p><strong>Conclusions: </strong>For kidney health care providers, targeted education and resources, clarity around roles and responsibilities, and long-term relationships with patients may help advance the cultural shift from treatment focus to integrating palliative care across the continuum of the illness journey.</p><p><strong>Trial registration: </strong>Not registered.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251350891"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12217565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life Cycle Assessment: A Primer for Kidney Professionals. 生命周期评估:肾脏专业人士入门。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-07-01 eCollection Date: 2025-01-01 DOI: 10.1177/20543581251347165
Saba Yousafzai, Rehan Sadiq, Kasun Hewage, Andrea J MacNeill, Caroline E Stigant

Background: The growing emphasis on low-carbon, sustainable health care systems is driving the integration of environmental sustainability into clinical practice and research. This shift necessitates clinician literacy in health care sustainability, particularly in methodologies for assessing environmental impacts.

Objective: To introduce health care professionals to life cycle assessment (LCA) as a tool for evaluating environmental impacts in clinical contexts and to illustrate its application through a case study on hemodialysis therapies.

Design: A qualitative assessment of LCA methodology, including its fundamental principles, stages, and applications in health care.

Setting: Hemodialysis materials were collected from In-Centre and Home Dialysis units at Vancouver General Hospital.

Patients/sample/participants: No patients are directly involved in this work; samples of unused hemodialysis materials were collected for process assessment. The target audience is health care professionals, particularly those involved in kidney care, who need to interpret LCA results for informed decision-making.

Methods: Overview of LCA, an internationally standardized methodology that evaluates the environmental impacts of products and processes over their entire life cycle, is presented. The 4 stages of LCA, the key environmental impact categories it assesses, and guidelines for appropriate interpretation and use are explored.

Results: Life cycle assessment provides numerous midpoint data, mechanisms by which damages occur to endpoints, including human health and environments. The case study comparing home versus in-center hemodialysis demonstrates how LCA findings can inform decision-making in kidney care.

Limitations: The interpretation of LCA results requires an understanding of its methodology and limitations. The accuracy of LCA outcomes depends on the quality and scope of data used in the assessment.

Conclusions: As LCA is increasingly applied in clinical settings, health care professionals must develop the skills to critically evaluate and apply its findings. This primer equips kidney care professionals with essential knowledge of LCA methodology, supporting the integration of environmental sustainability into clinical practice.

Trial registration: Not applicable.

背景:越来越强调低碳、可持续的卫生保健系统正在推动环境可持续性融入临床实践和研究。这一转变要求临床医生具备卫生保健可持续性方面的知识,特别是评估环境影响的方法。目的:向卫生保健专业人员介绍生命周期评估(LCA)作为评估临床环境影响的工具,并通过血液透析治疗的案例研究说明其应用。设计:对生命周期分析方法进行定性评估,包括其基本原则、阶段和在卫生保健中的应用。环境:血液透析材料从温哥华综合医院的中心和家庭透析单位收集。患者/样本/参与者:无患者直接参与本研究;收集未使用的血液透析材料样品进行工艺评估。目标受众是医疗保健专业人员,特别是那些涉及肾脏护理的人,他们需要解释LCA结果以做出明智的决策。方法:LCA的概述,一个国际标准化的方法,评估产品和过程在其整个生命周期的环境影响,提出。本文探讨了LCA的四个阶段、评估的主要环境影响类别,以及适当解释和使用的指导方针。结果:生命周期评估提供了许多中点数据,以及对端点(包括人类健康和环境)造成损害的机制。比较家庭和中心血液透析的案例研究表明,LCA的发现可以为肾脏护理的决策提供信息。局限性:对LCA结果的解释需要了解其方法和局限性。LCA结果的准确性取决于评估中使用的数据的质量和范围。结论:随着LCA在临床环境中的应用越来越多,卫生保健专业人员必须培养批判性评估和应用其发现的技能。本引物装备肾脏护理专业人员与LCA方法的基本知识,支持环境可持续性整合到临床实践。试验注册:不适用。
{"title":"Life Cycle Assessment: A Primer for Kidney Professionals.","authors":"Saba Yousafzai, Rehan Sadiq, Kasun Hewage, Andrea J MacNeill, Caroline E Stigant","doi":"10.1177/20543581251347165","DOIUrl":"10.1177/20543581251347165","url":null,"abstract":"<p><strong>Background: </strong>The growing emphasis on low-carbon, sustainable health care systems is driving the integration of environmental sustainability into clinical practice and research. This shift necessitates clinician literacy in health care sustainability, particularly in methodologies for assessing environmental impacts.</p><p><strong>Objective: </strong>To introduce health care professionals to life cycle assessment (LCA) as a tool for evaluating environmental impacts in clinical contexts and to illustrate its application through a case study on hemodialysis therapies.</p><p><strong>Design: </strong>A qualitative assessment of LCA methodology, including its fundamental principles, stages, and applications in health care.</p><p><strong>Setting: </strong>Hemodialysis materials were collected from In-Centre and Home Dialysis units at Vancouver General Hospital.</p><p><strong>Patients/sample/participants: </strong>No patients are directly involved in this work; samples of unused hemodialysis materials were collected for process assessment. The target audience is health care professionals, particularly those involved in kidney care, who need to interpret LCA results for informed decision-making.</p><p><strong>Methods: </strong>Overview of LCA, an internationally standardized methodology that evaluates the environmental impacts of products and processes over their entire life cycle, is presented. The 4 stages of LCA, the key environmental impact categories it assesses, and guidelines for appropriate interpretation and use are explored.</p><p><strong>Results: </strong>Life cycle assessment provides numerous midpoint data, mechanisms by which damages occur to endpoints, including human health and environments. The case study comparing home versus in-center hemodialysis demonstrates how LCA findings can inform decision-making in kidney care.</p><p><strong>Limitations: </strong>The interpretation of LCA results requires an understanding of its methodology and limitations. The accuracy of LCA outcomes depends on the quality and scope of data used in the assessment.</p><p><strong>Conclusions: </strong>As LCA is increasingly applied in clinical settings, health care professionals must develop the skills to critically evaluate and apply its findings. This primer equips kidney care professionals with essential knowledge of LCA methodology, supporting the integration of environmental sustainability into clinical practice.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251347165"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Program Report-Transplant Manitoba Adult Kidney Program Cutting Costs, Not Corners: Value of Quality Improvement Initiatives. 项目报告-马尼托巴成人肾脏移植项目削减成本,而不是投机取角:质量改进倡议的价值。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-07-01 eCollection Date: 2025-01-01 DOI: 10.1177/20543581251341712
Christie Rampersad, Aaron Trachtenberg, James Shaw, Nancy Dodd, Krista Maxwell, Martin Karpinski, Chris Wiebe, Peter Nickerson, Julie Ho
<p><strong>Purpose: </strong>Provision of high-quality, evidence-based patient care that is sustainable for our universal health system is a core Canadian Medical Education Directions for Specialists (CanMEDs) expectation. The Transplant Manitoba Adult Kidney Program (TMAKP) embraced this responsibility by addressing inefficiencies in its practices through multipronged quality improvement (QI) strategies, including reducing unnecessary interventions, implementing innovative strategies, and aligning clinical practices with emerging evidence. Using seamlessly embedded continuous QI and clinical research with a learning health system, the program achieved substantial cost savings and increased opportunities for deceased donor kidney transplantation. The purpose of this analysis is to measure the cost savings associated with these QI initiatives.</p><p><strong>Sources of information: </strong>Transplant Manitoba Adult Kidney Program database and quality metrics, Manitoba Health Physician's Manual (April 1, 2024), PubMed.</p><p><strong>Methods: </strong>To quantify the potential cost savings, we employed a 3-pronged approach. For reduced testing, a cost-counting exercise was conducted using historical transplant activity (831 prevalent and 83 incident patients) to project number of tests avoided and direct costs per test. Second, cost savings for generic mycophenolic acid was presented as ratios of generic to brand name drug costs, and projected cost savings for prevalent patients receiving average dosing. Third, for increased kidney utilization, cost savings per kidney transplant were derived from published studies and extrapolated using predicted additional transplants. Net health care system savings across payers were assessed at a 1-year time horizon.</p><p><strong>Key findings: </strong>The TMAKP reduced unnecessary testing, adopted generic medications, and implemented innovative strategies, achieving $2,530,026 in projected annual 1-year cost savings. These QI initiative savings augment the overall cost-effectiveness of kidney transplantation compared with dialysis. Implementing evidence-based protocols using personalized risk-stratified approaches to viral monitoring and novel donor-specific antibody surveillance strategies aligned testing with clinical risk while minimizing patient burden, highlighting the benefits of seamlessly integrating research with learning health systems. Programs for hepatitis C-viremic donor kidneys and age-targeted allocation increased transplant opportunities and optimized deceased donor organ use. Manitoba's initiatives demonstrate the importance of validation, stakeholder engagement, and iterative adaptation in driving sustainable improvements in transplantation care. Critically, this requires the foresight of health care administrative systems to invest in effective and ongoing QI and embed research with clinical practice, to improve patient and health system outcomes.</p><p><strong>Limitations: </strong>This ana
目的:为我们的全民医疗系统提供可持续的高质量、循证的患者护理是加拿大医学教育专家方向(CanMEDs)的核心期望。马尼托巴成人肾脏移植项目(TMAKP)承担了这一责任,通过多管齐下的质量改进(QI)策略来解决其实践中的低效问题,包括减少不必要的干预,实施创新策略,并将临床实践与新出现的证据结合起来。使用无缝嵌入的连续QI和临床研究与学习健康系统,该项目实现了大量的成本节约,并增加了死者供体肾脏移植的机会。此分析的目的是度量与这些QI活动相关的成本节约。信息来源:马尼托巴成人肾脏移植项目数据库和质量指标,马尼托巴健康医生手册(2024年4月1日),PubMed。方法:为了量化潜在的成本节约,我们采用了三管齐下的方法。为了减少检测,使用历史移植活动(831例流行患者和83例意外患者)进行成本计算,以预测避免的检测数量和每次检测的直接成本。其次,仿制药霉酚酸的成本节约表现为仿制药与品牌药成本的比率,以及接受平均剂量的流行患者的预计成本节约。第三,为了提高肾脏利用率,每次肾脏移植的成本节约来自已发表的研究,并通过预测的额外移植来推断。在1年的时间范围内评估了支付者的医疗保健系统净储蓄。主要发现:TMAKP减少了不必要的检测,采用了仿制药,并实施了创新策略,预计每年可节省成本2,530,000美元。与透析相比,这些QI倡议的节省增加了肾移植的总体成本效益。实施基于证据的方案,采用个性化的风险分层方法进行病毒监测,采用新颖的供体特异性抗体监测策略,使检测与临床风险保持一致,同时最大限度地减少患者负担,突出将研究与学习型卫生系统无缝整合的好处。丙型肝炎病毒血症供体肾脏和年龄目标分配方案增加了移植机会并优化了死者供体器官的使用。曼尼托巴省的举措证明了验证、利益相关者参与和迭代适应在推动移植护理可持续改进中的重要性。至关重要的是,这需要卫生保健行政系统的远见卓识,投资于有效和持续的QI,并将研究与临床实践结合起来,以改善患者和卫生系统的结果。局限性:该分析受限于依赖于预计的成本节约,这需要通过实际审计来确认影响。此外,一些有价值的QI工作在改善患者预后的同时,可能会增加成本,这突出了在评估管理计划时需要平衡的观点。最后,该分析仅限于预计的成本节约,不评估临床结果、过程依从性或实施有效性。启示:这一经验突出了在加拿大公共资助的卫生系统中,卫生系统质量倡议在优化护理和资源利用方面的潜力。这些努力减少了不必要的检测,最大限度地减轻了患者负担,扩大了移植机会,说明了管理如何在财政责任与高质量的最先进患者护理之间取得平衡。通过实施基于证据的方案,TMAKP在一年内实现了额外的2,530,026美元的预计成本节约。未来的年度成本节约将继续在不断增长的普遍肾移植人口在马尼托巴省上升。这些节省下来的资金可以重新分配到其他关键的卫生保健服务中,扩大移植以外患者的可及性并改善其结果。
{"title":"Program Report-Transplant Manitoba Adult Kidney Program Cutting Costs, Not Corners: Value of Quality Improvement Initiatives.","authors":"Christie Rampersad, Aaron Trachtenberg, James Shaw, Nancy Dodd, Krista Maxwell, Martin Karpinski, Chris Wiebe, Peter Nickerson, Julie Ho","doi":"10.1177/20543581251341712","DOIUrl":"10.1177/20543581251341712","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Provision of high-quality, evidence-based patient care that is sustainable for our universal health system is a core Canadian Medical Education Directions for Specialists (CanMEDs) expectation. The Transplant Manitoba Adult Kidney Program (TMAKP) embraced this responsibility by addressing inefficiencies in its practices through multipronged quality improvement (QI) strategies, including reducing unnecessary interventions, implementing innovative strategies, and aligning clinical practices with emerging evidence. Using seamlessly embedded continuous QI and clinical research with a learning health system, the program achieved substantial cost savings and increased opportunities for deceased donor kidney transplantation. The purpose of this analysis is to measure the cost savings associated with these QI initiatives.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Sources of information: &lt;/strong&gt;Transplant Manitoba Adult Kidney Program database and quality metrics, Manitoba Health Physician's Manual (April 1, 2024), PubMed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;To quantify the potential cost savings, we employed a 3-pronged approach. For reduced testing, a cost-counting exercise was conducted using historical transplant activity (831 prevalent and 83 incident patients) to project number of tests avoided and direct costs per test. Second, cost savings for generic mycophenolic acid was presented as ratios of generic to brand name drug costs, and projected cost savings for prevalent patients receiving average dosing. Third, for increased kidney utilization, cost savings per kidney transplant were derived from published studies and extrapolated using predicted additional transplants. Net health care system savings across payers were assessed at a 1-year time horizon.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Key findings: &lt;/strong&gt;The TMAKP reduced unnecessary testing, adopted generic medications, and implemented innovative strategies, achieving $2,530,026 in projected annual 1-year cost savings. These QI initiative savings augment the overall cost-effectiveness of kidney transplantation compared with dialysis. Implementing evidence-based protocols using personalized risk-stratified approaches to viral monitoring and novel donor-specific antibody surveillance strategies aligned testing with clinical risk while minimizing patient burden, highlighting the benefits of seamlessly integrating research with learning health systems. Programs for hepatitis C-viremic donor kidneys and age-targeted allocation increased transplant opportunities and optimized deceased donor organ use. Manitoba's initiatives demonstrate the importance of validation, stakeholder engagement, and iterative adaptation in driving sustainable improvements in transplantation care. Critically, this requires the foresight of health care administrative systems to invest in effective and ongoing QI and embed research with clinical practice, to improve patient and health system outcomes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;This ana","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251341712"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12217574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Canadian Society of Nephrology Methods for Developing and Adapting Clinical Practice Guidelines: An Update. 加拿大肾脏病学会发展和适应临床实践指南的方法:更新。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-06-30 eCollection Date: 2025-01-01 DOI: 10.1177/20543581251346074
Somaya Zahran, Anna Mathew, Tyrone G Harrison, Arenn Jauhal, Michelle A Hladunewich, Reem A Mustafa

Purpose of the review: In this article, we provide an update on the Canadian Society of Nephrology's (CSN) process of identifying candidate topics and subsequent development of guidelines and commentaries using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT methodology. We revise the process of adapting existing guidelines with the inclusion of Kidney Disease Improving Global Outcomes (KDIGO) practice points. We also describe challenges of implementing guidelines and suggest solutions to address this with description of the CSN approach to disseminating and implementing guidelines.

Sources of information: The update reflects internal CSN documentation, stakeholder consultation for topic prioritization, and integration of methodological guidance from GRADE-ADOLOPMENT and international sources such as KDIGO.

Methods: We reviewed and synthesized the CSN's current guideline-development process, which includes a detailed examination of internal documentation, meeting summaries, and publicly available methodological frameworks with specific focus on the application of the GRADE-ADOLOPMENT approach. We analyzed how recommendations and practice points from KDIGO are assessed for relevance, updated based on Canadian context, and integrated into the final commentary using GRADE Evidence-to-Decision (EtD) frameworks. We also examined how conflict of interest is managed, how working groups are structured, and how recommendations are prioritized. In addition, we explored the CSN's evolving strategies for dissemination and implementation, including stakeholder engagement, survey feedback, and use of knowledge-translation tools.

Key findings: The CSN follows a transparent and rigorous process in guideline and commentary development. This comprehensive process considers the best-available evidence, balancing desirable and undesirable effects and patients' values, perspectives, and implications for the Canadian health care system including resources, equity, acceptability, and feasibility to maximize guideline implementation and advance the health of Canadians.

Limitations: The CSN updated methods reflect the current process and may not be generalizable to other guideline organizations. The impact of CSN commentaries on clinical practice, decision-making, and policy uptake has not been formally evaluated, limiting our understanding of their contribution to health system improvement and patient outcomes.

Implications: This review updates the CSN's processes for commentary working groups to identify relevant international guidelines, establish the level of agreement on included recommendations, incorporate perspectives of people with lived experience, and adjust the final product to the Canadian healthcare system before dissemination.

综述的目的:在这篇文章中,我们提供了加拿大肾脏病学会(CSN)使用分级推荐、评估、发展和评价(GRADE)-采用方法确定候选主题和随后制定指南和评论的最新进展。我们修改了适应现有指南的过程,纳入了肾病改善全球预后(KDIGO)实践要点。我们还描述了实施指南的挑战,并通过描述CSN传播和实施指南的方法,提出了解决这一问题的解决方案。信息来源:此次更新反映了CSN内部文件、利益相关方对主题优先次序的咨询,以及来自level - adolopdevelopment和国际来源(如KDIGO)的方法指导的整合。方法:我们回顾并综合了CSN目前的指导方针制定过程,其中包括对内部文件、会议摘要和公开可用的方法框架的详细审查,并特别关注grade - adolopdevelopment方法的应用。我们分析了如何评估KDIGO的建议和实践要点的相关性,根据加拿大的情况进行更新,并使用GRADE证据到决策(EtD)框架将其整合到最终评论中。我们还研究了如何管理利益冲突,如何组织工作组,以及如何确定建议的优先级。此外,我们还探讨了CSN在传播和实施方面不断发展的战略,包括利益相关者参与、调查反馈和知识翻译工具的使用。主要发现:CSN在指南和评论的制定过程中遵循透明和严格的流程。这一综合过程考虑了可获得的最佳证据,平衡了可取和不可取的效果以及患者的价值观、观点和对加拿大卫生保健系统的影响,包括资源、公平性、可接受性和可行性,以最大限度地实施指南并促进加拿大人的健康。局限性:CSN更新的方法反映了当前的过程,可能不能推广到其他指南组织。CSN评论对临床实践、决策和政策采纳的影响尚未得到正式评估,限制了我们对其对卫生系统改进和患者预后的贡献的理解。意义:本综述更新了CSN评论工作组的流程,以确定相关的国际指南,建立对所包括建议的一致程度,纳入有生活经验的人的观点,并在传播前调整最终产品以适应加拿大医疗保健系统。
{"title":"The Canadian Society of Nephrology Methods for Developing and Adapting Clinical Practice Guidelines: An Update.","authors":"Somaya Zahran, Anna Mathew, Tyrone G Harrison, Arenn Jauhal, Michelle A Hladunewich, Reem A Mustafa","doi":"10.1177/20543581251346074","DOIUrl":"10.1177/20543581251346074","url":null,"abstract":"<p><strong>Purpose of the review: </strong>In this article, we provide an update on the Canadian Society of Nephrology's (CSN) process of identifying candidate topics and subsequent development of guidelines and commentaries using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT methodology. We revise the process of adapting existing guidelines with the inclusion of Kidney Disease Improving Global Outcomes (KDIGO) practice points. We also describe challenges of implementing guidelines and suggest solutions to address this with description of the CSN approach to disseminating and implementing guidelines.</p><p><strong>Sources of information: </strong>The update reflects internal CSN documentation, stakeholder consultation for topic prioritization, and integration of methodological guidance from GRADE-ADOLOPMENT and international sources such as KDIGO.</p><p><strong>Methods: </strong>We reviewed and synthesized the CSN's current guideline-development process, which includes a detailed examination of internal documentation, meeting summaries, and publicly available methodological frameworks with specific focus on the application of the GRADE-ADOLOPMENT approach. We analyzed how recommendations and practice points from KDIGO are assessed for relevance, updated based on Canadian context, and integrated into the final commentary using GRADE Evidence-to-Decision (EtD) frameworks. We also examined how conflict of interest is managed, how working groups are structured, and how recommendations are prioritized. In addition, we explored the CSN's evolving strategies for dissemination and implementation, including stakeholder engagement, survey feedback, and use of knowledge-translation tools.</p><p><strong>Key findings: </strong>The CSN follows a transparent and rigorous process in guideline and commentary development. This comprehensive process considers the best-available evidence, balancing desirable and undesirable effects and patients' values, perspectives, and implications for the Canadian health care system including resources, equity, acceptability, and feasibility to maximize guideline implementation and advance the health of Canadians.</p><p><strong>Limitations: </strong>The CSN updated methods reflect the current process and may not be generalizable to other guideline organizations. The impact of CSN commentaries on clinical practice, decision-making, and policy uptake has not been formally evaluated, limiting our understanding of their contribution to health system improvement and patient outcomes.</p><p><strong>Implications: </strong>This review updates the CSN's processes for commentary working groups to identify relevant international guidelines, establish the level of agreement on included recommendations, incorporate perspectives of people with lived experience, and adjust the final product to the Canadian healthcare system before dissemination.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251346074"},"PeriodicalIF":1.6,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bayesian Analysis of Time-To-Event Data in a Cluster-Randomized Trial: Major Outcomes With Personalized Dialysate TEMPerature (MyTEMP) Trial. 聚类随机试验中事件发生时间数据的贝叶斯分析:个性化透析液温度(MyTEMP)试验的主要结果
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-06-28 eCollection Date: 2025-01-01 DOI: 10.1177/20543581251341710
Yongdong Ouyang, Bin Luo, Stephanie N Dixon, Ahmed A Al-Jaishi, P J Devereaux, Michael Walsh, Ron Wald, Merrick Zwarenstein, Sierra Anderson, Amit X Garg
<p><strong>Background: </strong>MyTEMP was a cluster-randomized trial to assess the effect of using a personalized cooler dialysate compared to standard temperature dialysate for potential cardiovascular benefits in patients receiving maintenance hemodialysis in Ontario, Canada.</p><p><strong>Objective: </strong>To conduct Bayesian analyses of the MyTEMP trial, which sought to determine whether adopting a center-wide policy of personalized cooler dialysate is superior to a standard dialysate temperature of 36.5°C in reducing the risk of a composite outcome of cardiovascular-related deaths or hospitalizations.</p><p><strong>Design: </strong>Secondary analysis of a parallel-group cluster-randomized trial.</p><p><strong>Setting: </strong>In total, 84 dialysis centers in Ontario, Canada, were randomly allocated to the 2 groups.</p><p><strong>Patients: </strong>Adult outpatients receiving in-center maintenance hemodialysis from dialysis centers participating in the trial.</p><p><strong>Measurements: </strong>The primary composite outcome was cardiovascular-related death or hospital admission with myocardial infarction, ischemic stroke, or congestive heart failure during the 4-year trial period.</p><p><strong>Methods: </strong>MyTEMP trial data were analyzed using Bayesian cause-specific parametric Weibull methods to model the survival time with 6 pre-defined reference priors of normal distributions on the log hazard ratio for the treatment effect (strongly enthusiastic, moderately enthusiastic, non-informative, moderately skeptical, skeptical, strongly skeptical). For each analysis, we reported the posterior mean, 2nd, 50th, and 98th percentiles of the treatment effects (hazard ratios) and 96% credible interval (CrI). We also reported the estimated posterior probabilities for different magnitudes of treatment effects.</p><p><strong>Results: </strong>Regardless of priors, Bayesian analysis yielded consistent posterior means and a 96% CrI. The posterior distribution of the hazard ratio was concentrated between 0.95 and 1.05, indicating there was probably no substantial difference between the 2 trial arms.</p><p><strong>Limitations: </strong>The interpretation of Bayesian methods highly depends on the prior distributions. In our study, the prior distributions were determined by 2 experts without a formal elicitation method. A formal elicitation is encouraged in future trials to better quantify experts' uncertainty about the treatment effect. In addition, we used cause-specific parametric Weibull methods to model survival time, as semi-parametric methods were not available in the standard Bayesian statistical software package at the time of analysis.</p><p><strong>Conclusions: </strong>Our Bayesian analysis indicated that implementing personalized cooler dialysate as a center-wide policy is unlikely to yield meaningful benefits in reducing the composite outcome of cardiovascular-related deaths and hospitalizations, regardless of prior expectations, whethe
背景:MyTEMP是一项聚类随机试验,旨在评估在加拿大安大略省接受维持性血液透析的患者中,使用个性化低温透析液与标准温度透析液相比对潜在心血管益处的影响。目的:对MyTEMP试验进行贝叶斯分析,该试验旨在确定在降低心血管相关死亡或住院的综合结局风险方面,采用全中心范围的个性化较冷透析液政策是否优于标准透析液温度36.5°C。设计:平行组群随机试验的二次分析。环境:加拿大安大略省共有84个透析中心被随机分为两组。患者:参与试验的透析中心接受中心内维持性血液透析的成年门诊患者。测量:在4年的试验期间,主要的综合结局是心血管相关死亡或因心肌梗死、缺血性中风或充血性心力衰竭住院。方法:使用贝叶斯原因特异性参数威布尔方法对MyTEMP试验数据进行分析,以治疗效果对数风险比正态分布的6个预定义参考先验(强烈热情、中度热情、非信息性、中度怀疑、怀疑、强烈怀疑)对生存时间进行建模。对于每个分析,我们报告了治疗效果的后验均值、第2、第50和第98百分位数(风险比)和96%可信区间(CrI)。我们还报告了不同程度治疗效果的估计后验概率。结果:无论先验情况如何,贝叶斯分析得出一致的后验均值和96%的CrI。风险比的后验分布集中在0.95 ~ 1.05之间,说明两个试验组之间可能没有显著差异。局限性:贝叶斯方法的解释高度依赖于先验分布。在我们的研究中,先验分布是由2位专家确定的,没有正式的启发方法。鼓励在未来的试验中进行正式的启发,以更好地量化专家对治疗效果的不确定性。此外,由于在分析时标准贝叶斯统计软件包中没有半参数方法,我们使用了特定原因的参数威布尔方法来建模生存时间。结论:我们的贝叶斯分析表明,无论先前对干预有效性的预期是乐观还是怀疑,将个性化的冷却透析液作为一项中心范围的政策,不太可能在减少心血管相关死亡和住院的综合结果方面产生有意义的好处。
{"title":"Bayesian Analysis of Time-To-Event Data in a Cluster-Randomized Trial: Major Outcomes With Personalized Dialysate TEMPerature (MyTEMP) Trial.","authors":"Yongdong Ouyang, Bin Luo, Stephanie N Dixon, Ahmed A Al-Jaishi, P J Devereaux, Michael Walsh, Ron Wald, Merrick Zwarenstein, Sierra Anderson, Amit X Garg","doi":"10.1177/20543581251341710","DOIUrl":"10.1177/20543581251341710","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;MyTEMP was a cluster-randomized trial to assess the effect of using a personalized cooler dialysate compared to standard temperature dialysate for potential cardiovascular benefits in patients receiving maintenance hemodialysis in Ontario, Canada.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To conduct Bayesian analyses of the MyTEMP trial, which sought to determine whether adopting a center-wide policy of personalized cooler dialysate is superior to a standard dialysate temperature of 36.5°C in reducing the risk of a composite outcome of cardiovascular-related deaths or hospitalizations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Secondary analysis of a parallel-group cluster-randomized trial.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;In total, 84 dialysis centers in Ontario, Canada, were randomly allocated to the 2 groups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Patients: &lt;/strong&gt;Adult outpatients receiving in-center maintenance hemodialysis from dialysis centers participating in the trial.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Measurements: &lt;/strong&gt;The primary composite outcome was cardiovascular-related death or hospital admission with myocardial infarction, ischemic stroke, or congestive heart failure during the 4-year trial period.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;MyTEMP trial data were analyzed using Bayesian cause-specific parametric Weibull methods to model the survival time with 6 pre-defined reference priors of normal distributions on the log hazard ratio for the treatment effect (strongly enthusiastic, moderately enthusiastic, non-informative, moderately skeptical, skeptical, strongly skeptical). For each analysis, we reported the posterior mean, 2nd, 50th, and 98th percentiles of the treatment effects (hazard ratios) and 96% credible interval (CrI). We also reported the estimated posterior probabilities for different magnitudes of treatment effects.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Regardless of priors, Bayesian analysis yielded consistent posterior means and a 96% CrI. The posterior distribution of the hazard ratio was concentrated between 0.95 and 1.05, indicating there was probably no substantial difference between the 2 trial arms.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;The interpretation of Bayesian methods highly depends on the prior distributions. In our study, the prior distributions were determined by 2 experts without a formal elicitation method. A formal elicitation is encouraged in future trials to better quantify experts' uncertainty about the treatment effect. In addition, we used cause-specific parametric Weibull methods to model survival time, as semi-parametric methods were not available in the standard Bayesian statistical software package at the time of analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our Bayesian analysis indicated that implementing personalized cooler dialysate as a center-wide policy is unlikely to yield meaningful benefits in reducing the composite outcome of cardiovascular-related deaths and hospitalizations, regardless of prior expectations, whethe","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251341710"},"PeriodicalIF":1.6,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Canadian Journal of Kidney Health and Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1